5/11/2017. Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts
|
|
- Moris Atkinson
- 6 years ago
- Views:
Transcription
1 Hepatitis C Virus Infection Management: Curing Is Caring Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts FORMATTED: 04/07/17 Slide 2 of 53 Financial Relationships With Commercial Entities Dr Kim has no relevant financial affiliations to disclose. (Updated 04/07/17) In this presentation I will discuss the off-label use of investigational direct-acting agents Acute HCV infection treatment Glecaprevir/pibrentasvir Slide 2 of 53 Learning Objectives After attending this presentation, learners will be able to: Describe modifiable risks for liver disease progression in HIV/HCV-coinfected individuals Optimize choice of antiviral regimens Describe rationale for enhanced screening, prevention, and treatment for HCV infection Slide 3 of 53 1
2 Audience response Slide 4 of 52 Slide 4 of 53 How long have you been involved in the treatment of HCV? 1. I have not treated HCV and we defer to hepatology 2. I have not treated HCV but others in my practice do 3. I have just started treating HCV within the last 2 years 4. I have been treating HCV for 2-5 years 5. I have been treating HCV for 5-15 years 6. I have been treating HCV for >15 years Slide 5 of 53 Slide 5 of 53 Estimates of prevalence in the United States Slide 6 of 53 NHANES - household based survey - ~ 3.2 million % unaware of infection Not included or underestimated in NHANES estimate: Homeless (142, ,610) Incarcerated (372, ,826) Veterans (1,237,461-2,452,006) Active military (6805) Healthcare workers (64, ,234) 2.7 to 5.0 million living with chronic HCV in the United States Number of Cases, millions Baby boomers Estimated HCV Cases account for >65% of cases 7.1 Conservative estimate Upper limit estimate Total Not Included in NHANES NHANES 0. CDC data. Ann Intern Med 2006 Denniston M, et al. Ann Intern Med. 2014;160: Chak E, et al. Liver Int. 2011;31: Zalesak M, et al. PLoS One. 2013;8:e63959; Edlin B, et al. Hepatology
3 HCV deaths exceed those from 60 infectious conditions (death certificate data) Slide 7 of 53 (including HIV, pneumococcus) Ly et al. CID 2016 MMWR: Age distribution of newly reported confirmed cases of hepatitis C virus infection --- Massachusetts, 2002 and 2009 Slide 8 of 53 * N = 6,281; excludes 35 cases with missing age or sex information. N = 3,904; excludes 346 cases with missing age or sex information. Source: Onofrey et al MMWR: May 6, 2011 / 60(17); HIV outbreak among PWID in the U.S. Overlaid upon a network of HCV transmission 135 cases as of report Investigation triggered by HIV surveillance Injection of oxymorphone Multigenerational use of injection drugs 84.4% (114/135) diagnosed with HCV infection Slide 9 of 53 Need for HCV prevention and vaccine! 3
4 A perfect storm for sexual HCV transmission: HIV+MSM Slide 9 of 52 Slide 10 of 53 Bloody practices Semen exposure Other STDs Sex Drugs Crystal methamphetamine Sildenafil Internet HIV Higher levels of virus in plasma and semen Immune deficiency, especially at GI mucosa Take home points: screening Slide Slide 109 of of 52 Slide 11 of 53 HCV is a common chronic infection and a candidate for screening Mostly asymptomatic Major cause of liver disease and leading cause of mortality in US Screening is effective, life-saving for those with advanced liver disease, also costeffective Whom to screen? Baby boomers born between 1945 / 1965 Those with past and ongoing risk factors (see prior list) Injection drug use (people who inject drugs) HIV+ men who have sex with men Screen highest risk patients yearly to identify early and prevent onward transmission HCV RNA for those already HCV Ab positive Slide 12 of 53 Goal of Treatment The goal of treatment of HCV-infected persons is to reduce all-cause mortality and liver-related health adverse consequences, including end-stage liver disease and hepatocellular carcinoma, by the achievement of virologic cure as evidenced by a sustained virologic response. Recommendations for When and in Whom to Initiate Treatment Treatment is recommended for all patients with chronic HCV infection, except those with short life expectancies that cannot be remediated by treating HCV, by transplantation, or by other directed therapy. Patients with short life expectancies owing to liver disease should be managed in consultation with an expert. Adapted from 4
5 Components of HCV care Slide 13 of 53 Coffee tied to lower mortality in French HIV/HCV coinfected patients Slide Slide 139 of of Slide 14 of 53 French ANRS HEPAVIH cohort n=1035 followed for median 5 years deaths (N=77) HCV-related causes 42.8% non-aids, non-hcc cancer 11.7% AIDS 10.4% ahr for death: Unstable housing 3.7 CD4 =< HCV cured 0.2 female gender or fewer EtOH drinks or more coffee 0.5 Carrieri et al. CROI 2016 Abstract #549 Take home points: evaluation Slide 15 of 53 Care for HCV is not all about treatment Preventing transmission (and harm reduction) critical to avoid re-infection Preventing liver progression Avoid alcohol Avoid weight gain (fatty liver) Coffee probably beneficial Avoid HIV Anticipating toxicities, managing drug/drug interactions Prognosis Noninvasive liver staging is now available ID doctors (and PCPs) will be critical in addressing the provider shortage 5
6 Identifying and Managing Interactions Slide 16 of 53 Kiser JJ, Burton JR, Jr, Everson GT. Nature Reviews Gastroenterol Hepatol 2013;10: Slide 17 of 53 HBV reactivation Slide 18 of 53 HBV flares (abrupt increase in ALT) preceded by HBV DNA increase institution or withdrawal of immunosuppression HBV core IgM may be positive Steroids, transplant, chemotherapy / biologics (esp. anti-cd20 Ab) Rare cases with HCV antiviral therapy (8-12 weeks into treatment) Reported with core-ab only but rate is likely extremely low Monitoring versus prophylaxis Treat HBSAg positive patients who meet AASLD criteria Prophylaxis or closely monitor those who do not meet AASLD criteria Monitor cab only, LFTs 8 and 12 weeks Lok et al. AASLD Guidelines 2009; Hammond et al. Biol Blood Marrow Transplant 2009; Wright et al. Am J Transplant 2014; Sulkowski et al. CID 2016; Wang et al. Clin Gastro Hep
7 Potential Therapeutic Targets in the HCV Replication Cycle Slide 20 of 53 Transport and release Fusion and uncoating HCV RNA Viral assembly Translation RNA replication NS5B polymerase inhibitors NS5A inhibitors Polyprotein processing NS2 NS4B NS3/4A protease inhibitors CypA NS5B NS3 NS5A NS4B NS2 NS3 NS5A NS5B HCV NS proteins NS5A inhibitors Adapted from slide courtesy Ray Chung Worldwide genotype distribution Slide 21 of 53 Possible combinations of HCV treatments then are applied to different viral genotypes Slide 22 of 53 PEG IFN GT3 10% GT4 4% GT2 9% BOC TLV SMV LDV VOX VEL PRV/r OBV DCV GZR EBR GCV PBV GT1 77% DSV Abbreviations: GT = genotype; PEG IFN = pegylated interferon; = ribavirin PIs: BOC = boceprevir, TLV = telaprevir, SMV = simeprevir; VOX = voxilaprevir; PRV = paritaprevir; GZR = grazoprevir; GCV = glecaprevir. Pharmacologic booster: r = ritonavir; NS5A: LDV = ledipasvir; VEL = velpatasvir; OBV = ombitasvir; DCV = daclatasvir; EBR = elbasvir; PBV = pibrentasvir; NS5B nonnucleoside: DSV = dasabuvir; NS5B nucleotide: = sofosbuvir 7
8 Predictors of relapse to sofosbuvir-based regimens Slide 23 of week FISSION POSITRON FUSION VALENCE n= week VALENCE n=247 PEG 12 week ATOMIC NEUTRINO n=339 Who will do poorly with currently-available based regimens? SVR12= undetectable HCV RNA at 12 weeks after cessation of therapy Six factors associated with relapse: Treatment-experienced IL28B non-cc Male sex Weight > 75 kg Cirrhosis High viral load >800,000 IU/mL Foster et al. EASL 2014 Abstract 66 Antiviral HCV treatments (FDA-approved as of June 28, 2016) Slide 24 of 53 Monotherapies IFN-2a IFN-2b PEG-IFN 2a Combination Therapies Daclatasvir (DCV) + Sofosbuvir () IFN-2a + Ribavirin (GT1,3)* IFN-2b + Ribavirin Elbasvir (EBR) / Grazoprevir (GZR) PEG-IFN 2a + Ribavirin* PEG-IFN 2b + Ribavirin (FDC GT1,4)* PEG-IFN 2b PEG-IFN + ribavirin plus either: Boceprevir (GT1) Telaprevir (GT1) Simeprevir (GT1) In combination with other agents: Sofosbuvir Ledipasvir (LDV) / Sofosbuvir () (FDC, GT1,4,5,6)* Paritaprevir / ritonavir / ombitasvir (FDC) + dasabuvir PrOD (GT1) Paritaprevir / ritonavir / ombitasvir (FDC) PrO (GT4) Simeprevir (SMV) + Sofosbuvir () *approved for HIV/HCV coinfection (GT1) approved for GT1 - decompensated and post-liver transplant Sofosbuvir () / Velpatasvir (VEL) approved for decompensated (FDC, All GTs) Antiviral HCV treatments (FDA-approved as of June 28, 2016) Slide 25 of 53 LDV Combination Therapies Daclatasvir (DCV) + Sofosbuvir () (GT1,3)* Elbasvir (EBR) / Grazoprevir (GZR) (FDC GT1,4)* Ledipasvir (LDV) / Sofosbuvir () (FDC, GT1,4,5,6)* Paritaprevir / ritonavir / ombitasvir (FDC) + dasabuvir PrOD (GT1) Paritaprevir / ritonavir / ombitasvir (FDC) PrO (GT4) EBR GZR PTV/r OBV DSV VEL Simeprevir (SMV) + Sofosbuvir () (GT1) Sofosbuvir () / Velpatasvir (VEL) (FDC, All GTs) 8
9 >90% cure rates for Genotype 1 Slide 26 of 53 PTV/r SVR ~95% of genotype 1 patients can be cured with current regimens 455/473 OBV DSV 286/ / /214 LDV 102/ /215 SAPPHIRE-I SAPPHIRE-II TURQUOISE-II ION-1 ION-2 ION-3 LDV ION-1 and 2: arms not shown but did not enhance SVR, therefore not necessary for many receiving LDV/ Cirrhotics (TURQUOISE) 24 weeks 95.9% SVR Tx-Exp (ION-2) 24 wks LDV/ 108/109 SVR no cirrhosis naive no cirrhosis null responder 55% 100% cirrhosis 16% cirrhosis naive 20% cirrhosis Tx-Exp no cirrhosis naive SAPPHIRE 1 Feld et al. NEJM 2014, SAPPHIRE 2 Zeuzem et al. NEJM 2014, ION 1 Afdhal et al. NEJM 4/12/2014, ION 2 Afdhal et al. NEJM 2014; 370(16):1483, ION 3 Kowdley et al. NEJM 4/12/2014. SAPPHIRE/TURQUOISE are 12 week arms only. ION studies are sparing arms only Major considerations for ledipasvir/sofosbuvir Slide 27 of 53 Few data for patients with egfr<30 Cirrhosis: No dose adjustment or for treatment-naive patients Drug interactions: Avoid coadministration with amiodarone - life-threatening bradycardia Avoid with oxcarbazepine, carbamazepine, rifampin, St. John s wort Antacids lower absorption of ledipasvir Avoid PPIs if possible Maximum dose omeprazole 20 mg If on omeprazole, take LDV/ with something acidic Shortening ledipasvir/sofosbuvir to 8 weeks Slide 28 of 53 ION-3 trial established 94% cure rate with eight weeks of therapy with ledipasvir/sofosbuvir for patients naive to therapy; non-cirrhotic Most relapses occurred in those with HCV RNA > 6,000,000 IU/mL Real-world (non-rct) data confirm efficacy of 8 weeks 94-98%,? selecting favorable patients Generally African-Americans under-represented Subanalysis showed ~91% SVR rate in African Americans using 8 weeks Caution regarding those with HIV, black patients, or certain characteristics Few data in HIV/HCV coinfection, especially African- American455/ / / / / /215 Care with F3 patients as they may be harboring F4 From adherence and cost standpoint, 8 weeks is attractive ION 3 Kowdley et al. NEJM 2014; Wilder et al. compared to 12 weeks Hepatology 2016; Ingiliz et al. ClD 2016; Lai et al. Drugs 2017; Kowdley et al. Hepatology 2017; 9
10 Extension of therapy beyond 12 weeks of PrOD necessary for cirrhotic patients with GT1a Slide 29 of weeks 24 weeks TURQUOISE II 100% cirrhosis PTV/r OBV DSV PTV/r OBV DSV SVR /64 14/15 13/13 52/56 11/11 10/10 40/50 39/42 Partial Null Naive Relapse not necessary for 1b FDA Warning issued regarding rare cases of decompensation in CTP-A cirrhosis Poordad et al. TURQUOISE II, NEJM PrOD for 8 weeks for 1b patients with easier characteristics: GARNET Slide 30 of 53 PRV/r OBV DSV 8 weeks SVR / / /162 ITT mitt-gt mitt-gt-nvf ITT = intention to treat mitt-gt (3 excluded for not having 1b) mitt-gt-nvf (denominator excludes non 1b and 1 premature discontinuation Welzel et al.easl Special Conference 2016 Major considerations for PrOD Slide 31 of 53 For treatment-naive patients, generally unnecessary for GT1b 12 weeks for most patients 8 weeks for treatment naive, GT1b without cirrhosis Cirrhosis: Naive patients still may receive 12 weeks Safety concern with cirrhosis raised in post-marketing phase Avoid with decompensated cirrhosis Drug interactions: Multiple ritonavir-related drug interactions 10
11 Slide 32 of 53 C-EDGE: elbasvir/grazoprevir is a and nucleoside/nucleotide sparing 12- week regimen for GT 1/4 HCV EBR GZR 12-wks Treatment naive Mean age 52 46% women 37% nonwhite 22% cirrhosis % SVR12 50 Serious AE n=12, none drug-related / / /131 18/18 8/10 All Patients GT 1a GT 1b GT 4 GT6 9 relapsers, 1 breakthrough in 1a Similar SVR for n=218 HIV co-infected individuals on DTG/RAL/RPV Zeuzem et al. Ann Intern Med 2015; Rockstroh et al. Lancet HIV 2015 Cirrhosis does not impact SVR rates for 12 weeks of EBR/GZR Slide 33 of 53 GZR EBR No cirrhosis Cirrhosis AEs are similar between cirrhotic and non cirrhotic patients in these trials % SVR /246 68/70 34/35 32/34 175/183 35/35 C-EDGE C-SALVAGE HIV C-EDGE Zeuzem et al. Ann Intern Med 2015; Rockstroh et al. Lancet HIV 2015; Buti et al. CID 2016; Jacobson et al. AASLD 2015 EBR/GZR - Resistance Associated Variants (RAVs) at NS5A positions 28, 30, 31, 93 associated with lower SVR Slide 34 of 53 EBR GZR } 28,30,31 } 93 Baseline testing for NS5A resistance recommended if using this regimen Jacobson et al AASLD 2015, San Francisco 11
12 EBR/GZR - extension of therapy to 16 weeks and addition of overcame resistance Slide 35 of 53 GZR EBR Jacobson et al AASLD 2015, San Francisco Major considerations for elbasvir/grazoprevir Slide 36 of 53 For treatment-naive patients, genotypes 1 and 4 12 weeks for most patients Extend 16 weeks and add for GT1a harboring NS5A resistance-associated substitutions NS5A mutations: M28A/G/T Q30D/E/H/G/K/L/R L31F/M/V Y93C/H/N/S Cirrhosis: Avoid with decompensated cirrhosis Drug interactions: Transporter issues with oxcarbazepine, carbamazepine, rifampin Excellent safety and efficacy in stage 4/5 chronic kidney disease Response rates for pangenotypic regimen: Genotypes 1-6 Slide 37 of weeks for GT1,2,4,5,6 19% compensated cirrhosis 32% nonresponders VEL weeks for GT3 No cirrhosis Cirrhosis SVR / / /116 34/35 41/41 GT1 GT2 GT4 GT5 GT6 8 week arms of phase II trial: lower SVRs at 100 mg VEL dos (81-88%) 0 160/163 Best available option for genotype 2/3 40/43 GT3 Naive 40/43 31/34 33/37 GT3 Tx Exp Feld et al. NEJM 2015; Foster et al. NEJM 2015; Everson et al. Ann Intern Med
13 Glecaprevir and pibrentasvir (G/P): novel pangenotypic regimen Slide 38 of 53 Glecaprevir (GCV) is a pangenotypic next-generation HCV protease inhibitor Pibrentasvir (PBV) is a pangentoypic next-generation NS5A inhibitor GCV PBV ENDURANCE-1 examined 8 versus 12 weeks in GT1 non-cirrhotic patients with or without HIV Zeuzem et al. AASLD 2016 Glecaprevir and pibrentasvir (G/P): novel pangenotypic regimen Slide 39 of 53 ENDURANCE-1 examined 8 versus 12 weeks in GT1 non-cirrhotic patients with or without HIV Zeuzem et al. AASLD 2016 A menu of options Slide 40 of 53 Due to regulations, no alcohol will be served Primo Protease boceprevir 44 telaprevir 12 grazoprevir 12 / 16 paritaprevir +ritonavir 12 / 24 simeprevir 12 / 24 NS5A inhibitors daclatasvir 12 / 24 elbasvir 12 / 16 ledipasvir 8 / 12 / 24 ombitasvir 12 / 24 Polymerase inhibitors dasabuvir 12 / 24 sofosbuvir 8 / 12 / 24 Notice: The consumption of raw or undercooked eggs, meat, poultry, seafood or shellfish, and certain combinations are not approved by the FDA for Hepatitis C Please ask your server whether Ribavirin 40 is suggested 13
14 Prix fixe menus? Slide 41 of 53 Due to regulations, no alcohol will be served Notice regarding protease inhibitors boceprevir and telaprevir will no longer be offered due to high calories, dysgeusia and/or allergic reactions Grilled Goose 8 weeks of GS-9857, pan-seared topped with velpatasvir flakes on a sofosbuvir backbone Abalone Veloute 12 weeks of paritaprevir, slow-boosted, infused with ombitasvir, served with twice-dosed dasabuvir chutney Mesclun Medley (nuc-free option) 12 weeks of sous-vide grazoprevir topped with fresh elbasvir salsa Notice: The consumption of raw or undercooked eggs, meat, poultry, seafood or shellfish, and some of these choices are not approved by the FDA for Hepatitis C Please ask your server whether Ribavirin 41 is suggested Slide 42 of 53 The continuum of care in HCV infection in the U.S. At least 3 million persons infected Slide 45 of 53 50% 38% Improving cascade necessary to reduce transmission, morbidity and mortality 23% 11% 6% 1% Adapted from Holmberg et al. NEJM
15 Incidence, prevalence and sustaining an epidemic Slide 46 of 53 Rising opiate use Lack of prevention services Asymptomatic infection Unknown serostatus Barriers to care, access restrictions and cost of treatment Can PWID be cured with novel HCV regimens? Slide 47 of 53 Dore et al. Ann Intern Med 2016 Treatment of recently active PWID with elbasvir/grazoprevir; on opiate agonist therapy, made 80% appointments 4 8 Dore et al. Annals of Internal Medicine
16 Dutch lifted restrictions on treatment in Nov 2015 Achieving 70% cure in HIV/HCV patients Slide 49 of 53 Women, former IDU less likely to be treated Boerekamps et al. CROI 2017 Abstract 136 What were the effects of de-restricting access to DAAs in the Netherlands? Slide 50 of 53 Late 2015: unrestricted access with very rapid uptake in Dutch HIV/HCV coinfection - ~70% treated No associated decrease in syphilis or LGV so behavior is an unlikely explanation indirect evidence of cure as prevention for HCV Rijnders et al. CROI Abstract 137LB Take home points regarding treatment Slide 51 of 53 Novel interferon-free and ribavirin-free paradigms Potent combinations can overcome biologic / host barriers to response 12 week regimens available for many patients Shortened courses for certain regimens if favorable traits present Pangenotypic 8-week regimen coming Special populations are being addressed: Treating high-risk populations may be a component of reducing incident infections Improving cascade of care and removing restrictions to access will be critical to maximize the impact of treatment 16
17 Resources Slide 52 of 53 Guidelines: IDSA Webinars: Hepatitis C Online Course: Liverpool website for drug interactions: Glossary Slide 53 of 53 baby-boomer = those born between 1945 and 1965 DAA = direct-acting antiviral DCV = daclatasvir DSV = dasabuvir EBR = elbasvir EtOH = alcohol GCV = glecaprevir GT = genotype LDV = ledipasvir HCC = hepatocellular carcinoma IFN = interferon IL28B CC = host genotype associated with response to interferon-based therapy IL28B non-cc = host genotypes associated with lower response to interferon-based therapy NHANES = National Health and Nutrition Examination Survey NS3/4A = protease NS5A = NS5A nonstructural protein NS5B = HCV nonstructural protein polymerase OBV = ombitasvir pangenotypic = activity and/or efficacy against all major HCV genotypes PEG IFN = pegylated interferon PBV = pibrentasvir PRV = paritaprevir r = ritonavir PWID = people who inject drugs = ribavirin SMV = simeprevir VOX = voxilaprevir GZR = grazoprevir VEL = velpatasvir = sofosbuvir Hepatitis C Virus Infection Management: Curing Is Caring Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts FORMATTED: 04/07/17 17
Hepatitis C in 2018: From Evolution to Revolution
Hepatitis C in 218: From Evolution to Revolution Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston, Massachusetts
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More informationShorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationHepatitis C: the 2015 Perspective for the Family Medicine Practitioner
Hepatitis C: the 2015 Perspective for the Family Medicine Practitioner Annie Luetkemeyer, MD Division of HIV,ID & Global Medicine San Francisco General Hospital Disclosures I have received research grant
More informationNew York State HCV Provider Webinar Series
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Dost Sarpel, MD Division of Infectious Disease Viral Hepatology Milford Regional Medical Center Objectives Review the epidemiology
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More informationDescription of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases
Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral
More information5/10/2016. Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients. HCV life-cycle and antiviral targets
5/1/216 Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients David L. Wyles, MD Associate Professor of Medicine University of California San Diego La Jolla,
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationNew York State HCV Provider Webinar Series. Treatment of HCV/HIV Co-Infection
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Objectives Review the epidemiology of HCV and HIV/HCV co-infection Discuss the burden of HIV/HCV co-infection Discuss the treatment
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationHepatitis C Elimination: Screening, Linkage and Treatment. Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas
Hepatitis C Elimination: Screening, Linkage and Treatment Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas Hepatitis C: Worldwide Presence Worldwide prevalence: 130-150 million Viral hepatitis
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationCases: Initial Treatment of Hepatitis C
Cases: Initial Treatment of Hepatitis C Kristen Marks, MD Assistant Professor of Medicine Weill Cornell Medical College New York, New York Off-Label Warning I will discuss the following off-label use in
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationTreating Hepatitis C-HIV Coinfected Patients Welcome to the Real World
Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World H. Nina Kim, MD MSc Associate Professor of Medicine University of Washington Division of Allergy & Infectious Diseases April 21, 2017
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationHepatitis C: a treatment revolution
Sunday, 10th July 2016 Michaelmas Cay 2 Room Concurrent 11 Health Innovation Hepatitis C: a treatment revolution Dr. Heather McNamee Hepatitis C a treatment revolution Dr Heather McNamee Medical Director
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More informationUniversal HCV treatment: Strategies for simplification
Universal HCV treatment: Strategies for simplification PARIS HEPATOLOGY CONFERENCE 3 January 217 Tarik Asselah (MD, PhD) Hepatology & Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures
More informationCase 1: Chronic Hepatitis C
Case 1: Chronic Hepatitis C Moderator Dawn Pease, MSN, RN, ANP-BC Seton Healthcare Family University Medical Center Brackenridge Brackenridge Specialty Clinics - Gastroenterology and Endocrinology Austin,
More informationTreating Hepatitis C Virus (HCV) Infection
Slide 1 of 42 Treating Hepatitis C Virus (HCV) Infection Susanna Naggie, MD, MHS Associate Professor of Medicine Duke Clinical Research Institute Durham, North Carolina Slide 3 of 42 Learning Objectives
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationCCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015
CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015 CCO Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases, November
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationHCV Drug Resistance: Regulatory Perspective
HCV Drug Resistance: Regulatory Perspective Patrick Harrington, PhD Senior Clinical Virology Reviewer Division of Antiviral Products, FDA/CDER 2016 HIV and Hepatitis Clinical Pharmacology Workshop Washington,
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationHCV Screening, Management, and Treatment Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management, and Treatment Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: November 14, 2018 Effective Date: January 1, 2019 This drug class prior authorization criteria have been
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationTreatment of Patients with HCV and HIV
Treatment of Patients with HCV and HIV BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Four Questions Is HIV/HCV
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationDisclosures. Lisa M. Chirch, MD, FIDSA has disclosed that she has served on advisory boards for Gilead Sciences and Melinta Therapeutics.
HEPATITIS C IN 2017 Lisa M. Chirch, M.D. Associate Professor of Medicine University of Connecticut Health Center A Local Performance Site of the New England AETC Disclosures Lisa M. Chirch, MD, FIDSA has
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Harvoni) Reference Number: CP.CPA.175 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationHCV Screening, Management and Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management and Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health Sciences Center
More informationCurrent HCV Treatment by Genotype Ira M. Jacobson, MD
Current HCV Treatment by Genotype Ira M. Jacobson, MD Director of Hepatology NYU School of Medicine Objectives To understand the prevalence of HCV and distribution of HCV genotypes Describe the HCV lifecycle
More informationProgram Disclosure. A maximum of 1.5 contact hours may be earned for successful completion of this activity.
Program Disclosure This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More information